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A B S T R A C T
Adiponectin, secreted by fat tissue, is down – regulated in obesity and may be involved in obesity-related disorders. It
has anti-inflammatory, antiatherosclerotic and antidiabetic effect. Obesity is a strong predictor for hypertension and car-
diovascular diseases. Recent studies showed that adiponectin level has important role in metabolic disorders, arterial
hypertension and ischemic heart disease but its effect on left ventricular hypertrophy (LVH) has not been fully clarified.
The aim of this research is to determine whether the protective effect of adiponectin against development of left ventricu-
lar hypertrophy is decreased in hypertensive overweight patients. The study included 61 adult, overweight hypertensive
patients, with body mass index in range 25–30 kg/m2. Patients had regular morning glucose serum values and regular
creatinine level. They were divided into four groups, according to sex and the presence of LVH. There were 16 female and
15 male hypertensive patients with LVH and 15 female and 15 male hypertensive patients without LVH, who were a con-
trol group. Glucose profile, lipidogram, creatinine clearance and anthropometric measures were determined in all pa-
tients. Cardiovascular measurements were taken applying two-dimensional ultrasound. Adiponectin serum level was
measured using enzyme immunoassay (ELISA). Results showed that adiponectin serum level was significantly lower in
hypertensive, overweight females and males with LVH than in the control groups without LVH. Adiponectin serum level
did not correlate significant with intraventricular or with posterior wall thickness of left ventricle. Hypoadiponectinemia
presents part of neurohumoral, non-haemodynamic system who contributes to obesity-related hypertension and left ven-
tricular hypertrophy development. Low adiponectin level together with others adipokines, cytokines and chemokines se-
creted by fat tissue could contribute to pathophysiologic changes of the myocardium via unknownmolecular mechanisms
yet.
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Introduction
Adipose tissue is the biggest endocrine organ. Obesity
is characterized by uncontrolled expansion of adipose tis-
sue that secretes numbers of cytokines known as adipo-
cytokines¹. It has autocrine, paracrine and endocrine
functions². Disregulation of that secretion leads to obe-
sity-related disorders including metabolic syndrome³, di-
abetes, atherosclerosis, hypertension and cardiovascular
diseases4. Adiponectin, known also as Acrp30, apM1,
AdipoQ or GBP28, is an adipocytokine that is down-regu-
lated in obesity. It exists in three different high-order com-
plexes: high molecular weight form (HMW), low molecu-
lar weight form (hexamer) and trimetric form¹. Critical
mediators for adiponectin signaling are found in the skel-
etal muscles (ADIPOR1) and the liver (ADIPOR2)¹.
APPL1, an adaptor molecule, interacts with the intra-
cellular fragment of AdipoR1. Expression of APPL1 is
ubiquitous, which may reflect widespread relevance of
adiponectin signaling in various tissues¹. Research sho-
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wed that mouse, rat and human cardiomyocytes pro-
duced mRNA for adiponectin and adiponectin receptors
1 and 25.
Adiponectin has anti-inflammatory, antiatherosclero-
tic and antidiabetic effect6. Plasma concentrations reveal
sexual dimorphism, with females having higher levels
than males6. It is important to stress that action of sex-
ual steroid hormons (protective role of estrogen) on me-
chanisms of obesity related cardiovascular diseases (vas-
cular receptors and activity) are not clear yet enough7.
Adiponectin plasma level correlates negatively with body
mass index and with visceral adiposity, as well as with se-
rum triglycerides and small dense low-density lipopro-
tein (LDL), while it correlates positively with high-den-
sity lipoprotein (HDL)6.
Adiponectin affects sympathetic nervous system ac-
tivity via central regulation. Alterations in fat accumula-
tion in intraabdominal organs, such as visceral adipose
tissue and the liver, send afferent neuronal signals to the
brain, leading to modulation of sympathetic tonus8. In
that way, these humoral and neuronal signaling path-
ways communicate with each other8, causing changes in
blood pressure and sympathetic nerve activity¹. Low
adiponectin serum level leads to hypertension through
endothelial dysfunction and NO decrease causing vaso-
constriction and by overproduction of angiotensin II¹.
Adiponectin can have important role in protection aga-
inst cardiac hypertrophy in conditions of cardiac over-
load such as hypertension, hypertrophic cardiomyopathy
and ischemic heart disease9. Molecular basis linking obesity
with cardiovascular diseases has not been fully clarified10.
Materials and Methods
Patients
The research included 61 adult patients. They were
divided into four groups according to sex and the exis-
tence of left ventricular hypertrophy (LVH): there were
16 female patients with LVH and 15 male patients with
LVH. In the control groups there were 15 females and 15
males without LVH. In all patients body mass index
(BMI) was in range 25–30 kg/m2.
All patients were hospitalized on Department for Car-
diovascular medicine because of first myocardial infarc-
tion. According to their medical records they had per-
sonal history of essential hypertension for at least five
years. All patients had second degree of arterial hyper-
tension pursuant to European society of hypertension/
European society of cardiology 2007. guidelines for the
management of arterial hypertension. The presence of
secondary hypertension was excluded in all patients.
Exclusion criteria for the study were glucose intoler-
ance, diabetes mellitus, increased creatinine level in the
morning serum, valvular heart disease and left ventricu-
lar ejection fraction below 50%. All women were post-
menopausal and possible effect of estrogen was excluded.
All patients were all without early and late acute com-
plications after myocardial infarction as arrhythmias,
pericarditis, heart failure, cardiogenic shock. They were
discharge from hospital fourteen days after acute event
in a stabile condition.
They were treated with nitrates, beta blockers, ACE
inhibitors and aspirins. According to recent studies, ACE
inhibitors and selective beta blockers increase plasma
adiponectin levels4 while there is very little evidence to
suggest direct effect of aspirin on adipocytes9.
Patient’s history, clinical examination, electrocardiog-
raphy, X-ray of the thorax, biochemical blood analysis,
adiponectin level and two-dimensional echocardiography
were taken for each patient. All patients gave their writ-
ten informed consent. The study was approved by ethical
committees of our institutions.
Anthropometric measurements
Weight and height were measured by standard tech-
niques. The most common methods for diagnosing over-
weight and obesity are based on BMI (kg/m²)11. Body
mass index was calculated as body weight divided by
height squared. Waist end hips circumference was taken
by tape measure. Waist circumference was measured at
the umbilical level, in the middle between the lowest rib
and the iliac crest. Hip circumference was measured at
the trochanter level12.
Biochemical blood analysis
Blood glucose level, serum creatinine level and lipido-
grame were measured in all patients. Blood samples for
biochemical analysis were taken in the morning, on an
empty stomach. All patients had normal blood glucose
values, measured five times during hospitalization. Also,
they all had regular creatinine serum level. Cholesterol,
triglyceride, LDL, HDL were measured before hypoli-
pemic therapy. Creatinine clearance was calculated using
Cockcroft-Gault equation.
Cardiovascular determinations
In all patients a 12-lead ECG was performed two
times a day to monitor coronary heart disease stabiliza-
tion. Also, X-ray of the thorax was taken to evaluate the
left ventricular enlargement.
Echocardiographic determinations were obtained by
two-dimensional ultrasound Siemens Acuson CV 70 with
cardiologic probe P4-2. During the examinations pa-
tients were lying in the left lateral position. Intraventri-
cular septum (IVS) and posterior wall thickness (PWT)
of the left ventricle were determined by M-mode techni-
que13. Ejection fraction was measured by Simpson Bi-
plane method, and all the patients had normal value,
which is 50% or higher.
Echocardiographic measurements were taken accord-
ing to Textbook of Clinical Echocardiography by Otto (3rd
edition, Elsevier Sounders 2004), where the referent
value defining LVH in both sexes was 12 mm or more.
The data were classified into two groups, regarding IVS
and PWT. Both patients with LVH and patients without
LVH were examined.
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Determination of adiponectin in serum
Blood samples for adiponectin were taken from all
subjects between 7 and 7:30 a.m. on the twelfth day after
myocardial infarction, on an empty stomach. Total circu-
lating adiponectin serum level was measured using en-
zyme immunoassay for quantitative determination of
human adiponectin, ELISA KAPME09, IN VITRO DI-
AGNOSTIC USE, Biosource Europe S.A, Nivelles, Bel-
gium. Majority of clinical studies involving adiponectin
and human diseases only describe the relationship be-
tween total circulating levels of adiponectin. Use of as-
says measuring total levels of adiponectin in large clini-
cal studies remains a legitimate approach6.
Statistical methods
Data are presented as mean±SD. All statistical tests
were two-sided and carried out to a significance level (P)
of 0.05. Statistical analysis were done by non-parametric
test according to samples size and test normality. Mann-
-Whitney test was used for statistical analysis of adipo-
nectin distribution in hypertensive patients with and
without LVH. Spearman method was used to assess
univariate relations. The value p<0.05 was considered
statistically significant. Data were prepared for analysis
in Microsoft Excel 2003. Statistical analysis was made by
SPSS 15.0 for Windows Evaluation Version and Stati-
stica 7.1.
Results
All patients were adults with similar build and regu-
lar blood glucose and serum creatinine levels. Demo-
graphic, anthropometric, biochemical and echocardio-
graphic data for all groups of patients are given in Table
1. All subjects were hypertensive males and females and
they were divided into four groups according to sex and
presence of LVH. First two groups were males and fe-
males with LVH and control groups were males and fe-
males without LVH. LVH is characterized by intraven-
tricular wall thickness, as the most significant indicator
of LVH, and by posterior wall thickness. Ejection fraction
(EF) was preserved in all patients, above 50%.
Results showed that adiponectin serum levels were
statistically significantly lower in hypertensive females
with left ventricular hypertrophy than in females with-
out LVH (p=0.009). Also, hypertensive males with left
ventricular hypertrophy had statistically significantly
lower adiponectin level than males without LVH (p=
0.035) (Figure 1).
Serum adiponectin level did not have significant neg-
ative correlation with intraventricular wall thickness in
females with LVH (p=0.790) as well as with posterior
wall thickness of the LV (p=0.803). Also, in males with
left ventricular hypertrophy there was no statistically
significant negative correlation between adiponectin se-
rum level and intraventricular wall thickness (p=0.649)
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TABLE 1









n 15 16 15 15
Age, years (range) 58±9 68±8 57±9 60±8
Weight (kg) 81.60±9.08 73.50±8.91 80.8±8.89 68.73±5.68
BMI (kg/m²) 26.56±1.48 27.41±2.07 26.46±1.83 26.50±1.80
Wc (cm) 101.13±6.23 96.06±6.90 98.2±8.58 89.26±8.81
Hc (cm) 101.40±4.26 101.69±5.87 99±7.69 97.93±6.76
Bg (mmol/L) 5.33±0.80 5.54±0.75 5.66±0.66 5.75±0.48
Serum creatinine (mmol/L) 79.93±14.72 72.56±14.62 76.53±10.37 74.86±10.61
Cc (mL/min) 103.96±20.29 92.77±26.24 108.67±19.44 92.24±22.62
Cholesterol (mmol/L) 5.15±1.82 5.81±1.35 5.38±1.11 5.38±1.50
Triglycerides (mmol/L) 1.99±0.99 1.86±0.83 2.07±1.59 1.82±0.814
LDL (mmol/L) 3.26±1.11 3.35±0.96 3.34±1.10 3.07±1.40
HDL (mmol/L) 1.02±0.13 1.22±0.62 1.11±0.34 1.20±0.33
Adiponectin level (mg/mL) 7.952±4.852 11.029±4.579 15.227±14.239 23.248±13.727
IVS (mm) 14.73±1.67 14.19±1.94 10.53±0.64 10.267±0.799
PWT (mm) 12.87±0.83 12.69±0.70 9.33±0.9 9.06±0.79
EF (%) 57.67±7.37 58.06±6.90 58±7.04 60.8±6.51
Mean±SD, unless otherwise stated
LVH – left ventricle hypertrophy, BMI – body mass index, Wc – waist circumference, Hc – hips circumference, Bg – blood glucose, Cc –
creatinine clearance, IVS –intraventricular septum, PWT – posterior wall thickness, EF – ejection fraction
and between adiponectin serum level and posterior wall
thickness of LV (p=0.831) (Figure 2 and 3).
Significant positive correlation was found between
HDL and adiponectin level (p=0.040) in males with LVH.
Significant negative correlation was found between LDL
and adiponectin level (p=0.042) in females without LVH
and between BMI and adiponectin level (p=0.031) in
males without LVH.
Discussion and Conclusion
Hemodynamic factors have been thus far known to
cause development of arterial hypertension and left ven-
tricular hypertrophy. However, it has been discovered
that neurohumoral, non-hemodynamic factors are also
significant in development of LVH, which offers new pos-
sibilities in both prevention and treatment.
This research presents the effect of adiponectin on de-
velopment of left ventricular hypertrophy in patients
with hypertension and obesity, in other words the influ-
ence of neurohumoral system on development of LVH.
Most studies up to the present have studied the role of
adiponectin in metabolic disorders, arterial hypertension
and coronary heart disease. This research included nor-
moglycemic persons who were overweight, with BMI in
range 25–30 kg/m2 in order to determine the role of
adiponectin and its serum level in patients who were not
excessively obese. In our opinion patients’ therapy did
not have significant influence on the results of this study
taking into consideration that all the patients included in
the study received only short-term therapy.
According to recent studies, adiponectin level can pre-
dict improvement of cardiac damage and function 7 days
after myocardial infarction14. This means that when the
samples were taken to determine adiponectin level in our
study, twelve days after coronary incident, there was no
evidence that it can influence on adiponectin level.
According to data obtained up to the present, some
studies have shown that adiponectin inhibits hypertro-
phic, extracellular signal-regulated kinase (ERK) in myo-
cardium through activating AMP-activated protein kina-
se (AMPK)15 and is beneficial in the setting of pathological
cardiac remodeling and acute cardiac injury16. Also, re-
search in mice has shown that adiponectin protects agai-
nst overload-induced and adrenergically induced cardiac
myocyte hypertrophy9. Obesity-related hypertension in
patients with hypoadiponectinemia develops through en-
dothelial dysfunction (low NO level, increased TNFá, in-
creased C-reactive protein), increased rennin-angiotensin

























Fig. 1. Differences between adiponectin level in hypertensive fe-
males and males with and without LVH.
Fig. 2. Nonsignificant correlation between intraventricular wall
thickness of left ventricle and adiponectin concentrations.
Fig. 3. Nonsignificant correlation between posterior wall thick-
ness of left ventricle and adiponectin concentrations. Fig. 4. Hypothesis: cardiovascular effect of hypoadiponectinemia.
system activity and sympathetic nervous system overactivity
(increased heart rate and peripheral vascular resistance)1.
According to acquired knowledge on local production
of adiponectin and its receptors in the myocardium,
which has been obtained mostly in experimental studies,
it is possible to assume that neurohumoral system repre-
sented by adipocytokines, and in our study by adiponectin,
is a crucial part of a complex system that influences the
function and pathophysiologic processes of the heart.
We proved significant difference between serum level
of adiponectin in hypertensive patients with marked
LVH in comparison to hypertensive patients without
LVH. Hypoadiponectinemia, in the group of males and
females with LVH, presents part of non-haemodynamic
system who influence on obesity-related hypertension
development and has part in the myocardial hypertrophy
development via unknown mechanisms yet. Low adi-
ponectin level could mean: lost of anti-inflammatory and
antiatherogenic effect on the vascular endothel – leading
to systemic hypertension and increased cardiomyocytes
hypertrophic signal – leading to myocardial hypertrophy.
Haemodynamic and non-haemodynamic factors (hypo-
adiponectinemia together with disregulation of other
pro-inflammatory and proatherogenic adipokines, cyto-
kines and chemokines secreted by fat tissue) contribute
to pathophysiologic changes of the myocardium (Figure
4). Present results and hypothesis need to be proved by
future investigations on molecular mechanisms level.
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SNI@ENA SERUMSKA KONCENTRACIJA ADIPONEKTINA – REDUCIRAN PROTEKTIVNI U^INAK
NA DEBLJINU STIJENKI LIJEVE KLIJETKE
S A @ E T A K
Stanje pretilosti karakterizirano je sni`enom koncentracijom adiponektina koja mo`e utjecati na razvoj bolesti po-
vezanih s debljinom. Adiponektin posjeduje antiinflamatorni, antiaterosklerotski i antidijabeti~ni u~inak, a debljina je
direktno povezana s razvojem hipertenzije i kardiovaskularnih bolesti. Najnovije studije pokazuju da adiponektin ima
va`nu ulogu u razvoju metaboli~kih poreme}aja, arterijske hipertenzije i koronarne bolesti, no u~inak na razvoj hiper-
trofije lijeve klijetke (HLK) jo{ nije razja{njen. Cilj istra`ivanja je utvrditi da li protektivni u~inak adiponektina je
smanjen u procesu razvoja hipertrofije lijeve klijetke kod hipertoni~ara s prekomjernom tjelesnom te`inom.U studiju je
uklju~en 61 hipertoni~ar s ITM 25–30 kg/m2. Pacijenti su imali uredne vrijednosti glukoze u serumu nata{te i kon-
centracije kreatinina. Podijeljeni su u ~etiri skupine, prema spolu i prisutnosti HLK: 15 mu{karca i 16 `ena s HLK, te
kontrole od 15 mu{karaca i 15 `ena bez HLK. Koncentracija glukoze, kreatinina, lipidogram i antropometrijska mjere-
nja u~injena su svim ispitanicima. Kardiovaskularna mjerenja u~injena su dvodimenzionalnim ultrazvukom. Koncen-
tracija adiponektina odre|ena je enzimatskim immunoassay testom (ELISA). Rezultati su pokazali da je koncentracija
adiponektina u serumu zna~ajno ni`a kod hipertenzivnih mu{karaca i `ena s HLK u odnosu na kontrolne skupine bez
HLK. Koncentracija adiponektina ne korelira signifikantno s debljinom zidova lijeve klijetke. Hipoadiponektinemija
predstavlja dio neurohumoralnog, nehemodinamskog sustava koji pridonosi razvoju hipertenzije i HLK povezane s
debljinom. Niska koncentracija adiponektina zajedno s drugim adipokinima, citokinima i kemokinima sintetiziranim u
masnom tkivu pridonosi patofiziolo{kim promjenamamiokarda putem jo{ nerazja{njenih molekularnih mehanizama.
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